Sequencing and molecular characterization of CTNCEC25, a China fixed rabies virus vaccine strain CTN-1 adapted to primary chicken embryo cells

Shimao Zhu, Chunhua Wang, Pei Zhang, Hui Li, Shan Luo and Caiping Guo*

Abstract

Background: Rabies virus is the main etiologic agent of the widespread neurological disease rabies. Recently, the China rabies virus vaccine strain CTN-1 adapted to chicken embryo cells, which has been designated as CTNCEC25, was obtained and demonstrated to have high immunogenicity. However, the full genome sequence of CTNCEC25 and its phylogenetic relationship with other rabies virus street and vaccine strains have not been characterized.

Results: The complete genome of CTNCEC25 was sequenced and analyzed. The length of CTNCEC25 genome is 11,924 nucleotides (nt), comprising a 3′ leader sequence of 59 nt, nucleoprotein (N) gene of 1,425 nt, phosphoprotein (P) gene of 989 nt, matrix protein (M) gene of 803 nt, glycoprotein (G) gene of 2,067 nt, RNA-dependent RNA polymerase gene (L) of 6,474 nt and a 5′ trailer region of 71 nt. A comparison of the entire genomes of CTN-1 and CTNCEC25 identified 16 nt substitutions and 1 deletion, resulting in 8 amino acid (aa) changes in the five structural proteins with one in L (aa 1602), two in M (aa 99 and 191) and six in mature G (aa 147, 333, 389, 421 and 485). The percentage homology of the CTNCEC25 genomic sequence with other fully sequenced rabies virus strains ranged from 81.4% to 99.9%. Phylogenetic analysis indicated that CTNCEC25 was more closely related with those recently isolated China street strains than other vaccine strains. Virus growth analysis showed that CTNCEC25 achieved high rate of propagation in cultured cells.

Conclusions: In this study, the complete genome of CTNCEC25 was sequenced and characterized. Our results showed that CTNCEC25 was more closely related to wild street strains circulating in China than other vaccine strains. Sequence analysis showed that the G protein ectodomain amino acid sequence identity between CTNCEC25 and other rabies virus strains was at least 90% identical. Furthermore, CTNCEC25 achieved high virus titers in cultured cells. Given that CTNCEC25 has high immunogenicity and induced strong protective immune response in animals, these results collectively demonstrated that CTNCEC25 is an ideal vaccine strain candidate for producing human vaccine with high quality and safety in China.

Keywords: Genome sequence, Rabies virus, CTNCEC25, Chicken embryo cell, Vaccine

Background

Rabies, which is an ancient global fatal central nervous system (CNS) disease, affects almost all kinds of mammals, including humans [1]. The mortality of rabies is almost 100%, and it is estimated that more than 55,000 people die from rabies worldwide annually, with about 95% of those deaths occurring in the developing world such as Asia and Africa (see WHO Fact Sheet No. 99). China has the second highest incidence of rabies after India, and a total number of 108,412 human rabies cases were recorded in China during the 55-year period between 1950 and 2004 [2].

Rabies virus (RABV) is the main causative agent of rabies and is the type species of the genus Lyssavirus of the family Rhabdoviridae. RABV has a non-segmented,
single-stranded negative-sense RNA genome of approximately 12 kb that encodes five structural proteins in the order (3' to 5') of nucleoprotein (N), phosphoprotein (P), matrix protein (M), glycoprotein (G) and RNA-dependent RNA polymerase (large protein, L) [3,4]. The viral RNA genome together with the N, P and L proteins forms a helical ribonucleoprotein (RNP) that is packaged into a bullet-shaped structure and wrapped by an envelope comprising an inner layer of the M protein and the transmembrane spike G protein [1]. While the RNP complex is the entity responsible for viral transcription and replication within the cytoplasm of the host cell, the G and M proteins play pivotal roles in viral assembly and budding [5,6].

The RABV G protein is the only viral protein exposed on the surface of the virus. Previous studies have established that G protein is not only the major determinant of viral pathogenicity but is also the major protective antigen that induces the production of virus-neutralizing antibodies (VNAs) responsible for the immune responses of the host [7-10]. Moreover, the G protein is also involved in the neurotropism of RABV [11-18]. A number of antigenic sites to which neutralizing monoclonal antibodies bind were mapped in the G protein, including antigenic site I (aa 231), II (aa 34 - 200), III (aa 330 - 357), IV (aa 264) and “a” (aa 342 - 343) [19]. In addition, a linear epitope named G5 was also identified in the G protein (aa 244 - 281) [20,21]. Among these antigenic sites, aa 147 and 333 have been shown to be critical for G protein function as mutation in either of these two sites significantly affected RABV antigenicity and pathogenicity [22,23]. Furthermore, a region between aa 164 to 303 of the Nishigahara strain G protein also plays an important role in virus pathogenicity for adult mice, with aa 242, 255 and 268 constituting the key residues [24,25].

Currently, the pathogenesis of RABV has not been fully elucidated and vaccination is the only effective method to protect against RABV infection. Since the first development of a rabies vaccine by Pasteur in the late 19th century, vaccination has been widely used in both domestic animals as well as reservoir species [26,27]. At present, a number of RABV strains were used for vaccine production in different countries. Four virus strains, CTN-1, aG, PM and PV, have been applied in human rabies vaccine production in China and CTN-1 and aG strains are Chinese domestic isolates [28]. The CTN-1 strain was first isolated from brain tissue of a patient with rabies from Zibo, Shandong province while the aG strain was obtained from a rabid dog in Beijing [28]. However, although both the CTN-1 and aG strains are indigenous to China, they have distinct phylogenetic relationship. Previous studies suggested that the aG strain was more closely related with strains in northern and northeast part of China and phylogenetic analysis based on the N gene showed that the aG strain mainly clustered with strains from Japan and America but distantly clustered with most China street strains while the CTN-1 strain clustered preferentially with China native street viruses [29,30], suggesting that the CTN-1 strain had closer genetic relationship with street viruses prevailing in China. It has been assumed that the efficiency of cross protection against the epidemic street virus conferred by rabies vaccine correlated with the homology between the vaccine strain and the challenge strains [31]. Therefore, the CTN-1 strain is theoretically more suitable for vaccine production than the aG strain in China.

Recently, a CTN-1 strain adapted to chicken embryo cells (CECs), which has been named CTNCEC25, was successfully obtained and demonstrated to have high immunogenicity and potency to induce a strong protective immune response in animals [32]. Besides, CTNCEC25 lost pathogenicity to adult mice by intracerebral inoculation [32]. In the present study, to gain more insight into the biological characteristics of CTNCEC25, the complete sequence of the CTNCEC25 strain was sequenced and characterized. Sequence comparison and phylogenetic analysis demonstrated that CTNCEC25 was more closely related with those recently isolated China RABV street strains than other vaccine strains commonly used in China. Virus growth curve showed that CTNCEC25 replicated stably and maintained high titers at cultured cells. Therefore, these results demonstrated the potential use of the CTNCEC25 strain for producing human rabies vaccine in China.

Results
The genome organization of the CTNCEC25 strain
Based on the nucleotide sequence determined using a total of 13 primer pairs (as shown in Table 1), the complete sequence of the CTNCEC25 strain was obtained and submitted to the NCBI GenBank (GenBank accession no. KJ466147). The genome length of CTNCEC25 was 11,924 nucleotides (nt) and the overall organization of the CTNCEC25 strain was similar to that of the parental CTN-1 strain except that it has one deletion in the poly A tail of the P gene and is summarized as follows: a 3’ leader region of 59 nt (1 - 59), N gene (60 - 1,484), P gene (1,487 - 2,475), M gene (2,481 - 3,283), G gene (3,289 - 5,355), L gene (5,380 - 11,853), and the 5’ trailer region of 71 nt (11854 - 11924). The coding sequence (CDS) of the five structural proteins are located as follows: 1,353-nt N protein (72 - 1,424), 894-nt P protein (1,516 - 2,409), 609-nt M protein (2,496 - 3,104), 1,575-nt G protein (3,316 - 4,890) and 6,387-nt L protein (5,407 - 11,793).

The comparison of the complete CTNCEC25 genomic sequence with those selected RABV strains available in
the GenBank was performed to investigate the relative similarity of the CTNCEC25 strain to other RABV strains (Table 2). The results showed that the percentage homology of the CTNCEC25 strain at nucleotide level with other full-length genomes ranged from 81.5% with SHBRV-18 strain to 99.9% with the parental CTN-1 strain, indicating high relatedness of the CTNCEC25 strain with other RABV strains (Table 3).

Sequence comparison of the genome of CTNCEC25 and CTN-1

To investigate in detail the sequence variation after the adaption of CTN-1 to CECs, the genome sequence of CTNCEC25 and the parental CTN-1 strain was compared and analyzed (Table 4). Compared to that of the CTN-1 strain, a total of 16 nucleotide substitutions and 1 deletion, which resulted in 8 aa residues changes in the five structural proteins, were identified in the CTNCEC25 strain. The G gene was the most varied gene of the CTNCEC25 strain with 7 nucleotide mutations. All the seven mutations except one in the G gene non-coding region (5251 nt), were non-synonymous which changed 5 aa residues in the G protein. In contrast, although the L gene possessed 6 nucleotide mutations, only one of them affected the amino acid sequence. In addition, the N gene has 1 synonymous mutation and the P gene has a deletion of one A nucleotide in the potential polyadenylation signal. The M gene has 2 mutations which affected 2 aa residues in M protein.

The finding that a deletion of one A nucleotide was occurred in the gene junction of P and M was unexpected as several studies have shown that a 3' - U-U-U-U-U-U-5' (U7) tract at the end of each gene was essential for the polyadenylated tail of the five structural protein genes and was well conserved in all these five structural protein genes [3,33]. To further investigate the heterogeneity of the gene junctions of P and M, the CTNCEC25 P gene was used to searched against the nucleotide sequences at the NCBI database and a total of 41 RABV strains with complete genome sequenced was selected to compare the sequence heterogeneity of the P-M gene junctions. The summary of the sequence analysis is shown in Figure 1. The sequence across the P-M junction was wild type (with U7 tract) in 34 of 41 genomes and the shortening of U7 tract to U6 was found in three genomes including CTNCEC25. In the rest four genomes that were not wild type, the U tract was extended to U8 in three and interrupted by a C residue (U5CU1) in one genome (Figure 1). The above data showed that mutations that are known to eliminate termination of transcription might be selected and preserved in virus population during evolution.

Structural features of the G protein of the CTNCEC25 strain

As the G protein is essential for viral pathogenicity, the G protein amino acid sequence variation between CTNCEC25 and CTN-1 was investigated. Compared to the CTN-1 G protein, amino acids Lys147, Arg333, Glu389, Pro421 and Ser485 were changed to Glu147, Gln333, Lys389, Gln421 and Pro485, respectively in the CTNCEC25 G protein (Table 4). Among these amino acids, Lys147 and Arg333 have been shown to be essential for the pathogenesis of RABV [11,34-38]. The results also imply that antigenicity would be affected in CTNCEC25.

To investigate the G protein ectodomain sequence identity of CTNCEC25 with other RABV street or vaccine strains, pairwise comparisons using the G protein ectodomain amino acid sequence was performed. The results showed that the identity of the G protein ectodomain sequence ranged from 90.0% to 99.1% between CTNCEC25 with other RABV strains (Table 5).

### Table 1 Primers used in this study

| Primer | Sequence (5’ to 3’) | Base position (bp)<sup>a</sup> |
|--------|---------------------|---------------------------------|
| LH-1 F  | TACGCTTAACCAAACTAAAGA | 1-1075                          |
| LH-1 R  | GGTGCACATGCGCGCAATA | 937-2038                         |
| LH-2 F  | TCCGTTCAATGGCGGCTGAGTT | 1927-2979                       |
| LH-2 R  | CTGCCATTCGGGCTTTTG | 2818-3890                        |
| LH-3 F  | GGAAGATCCTCGGAGGACAA | 3730-4766                        |
| LH-3 R  | TTGTCTGCACTCTTCTATGT | 4654-5735                        |
| LH-4 F  | GAGGGCATGAACTGGGTGTA | 5585-6623                        |
| LH-4 R  | GGTGTTGTAACGAGTCAGGCAGA | 6510-7599                    |
| LH-5 F  | TCATTGCGCTCGGCAGTAA | 7494-8661                        |
| LH-5 R  | TTGTCTCCTGCGGCAAGAT | 8560-9601                        |
| LH-6 F  | TGAGTCACTGACCCAGGCTTC | 9486-10630                     |
| LH-6 R  | TGAGTCACTGACCCAGGCTTC | 10532-11686                     |
| LH-10 F | TGGACGCTCAGCAGAGCGCGT | 11565-11925                     |
| LH-10 R | TGGACGCTCAGCAGAGCGCGT | 11565-11925                     |
| LH-11 F | ATGTTGTCGGATGCGATCA | 9486-10630                        |
| LH-11 R | ATGTTGTCGGATGCGATCA | 10532-11686                     |
| LH-12 F | GGAGGAATATCCCGGAGCGATA | 11565-11925                     |
| LH-12 R | GGAGGAATATCCCGGAGCGATA | 11565-11925                     |
| LH-13 F | GTTGGCTGACGATACCTCAGGTC | 11565-11925                     |
| LH-13 R | GTTGGCTGACGATACCTCAGGTC | 11565-11925                     |

<sup>a</sup>Position from the 5’ terminal region of the full-genome sequence of the CTN-1 strain.
Table 2 The RABV strains for which complete genome or the G gene sequence is available that were used in this study

| Virus strain | Accession no. | Isolate country | Length (bp) |
|--------------|--------------|-----------------|-------------|
| Vaccine strains |              |                 |             |
| CTNCEC25     | KJ466147     | China           | 11,924      |
| CTN-1        | FJ959397     | Zibo, China     | 11,925      |
| SR/9         | AF499686     | China           | 11,928      |
| SAG2         | EF206719     | France          | 11,928      |
| ERA          | EF206707     | Germany         | 11,931      |
| SAD B19      | M31046       | America         | 11,928      |
| HEP-Flury    | AB085828     | America         | 11,615      |
| FluryLEP     | DQ099524     | Germany         | 11,711      |
| PM1503       | DQ099525     | Germany         | 11,723      |
| PV           | M13215       | France          | 11,932      |
| RV-97        | EF542830     | Russia          | 11,932      |
| 3aG G        | L04522       | Beijing, China  | 1,575       |
| Street strains |            |                 |             |
| HN10         | EU643590     | Hunan, China    | 11,923      |
| BD06         | EU549783     | Hunan, China    | 11,924      |
| DRV          | DQ875051     | Jilin, China    | 11,863      |
| MRV          | DQ875050     | Henan, China    | 11,869      |
| FJ008        | FJ866835     | Fujian, China   | 11,924      |
| D01          | FJ712193     | Zhejiang, China | 11,925      |
| JX08-45      | GU647092     | China           | 11,922      |
| DRV-AH08     | HQ450385     | Anhui, China    | 11,924      |
| SHBRV 18     | AY705373     | America         | 11,923      |
| 8743THA      | EU293121     | Thailand        | 11,923      |
| NNV-RAB-H    | EF437215     | India           | 11,928      |
| Nishigahara  | AB044824     | Japan           | 11,926      |
| HM65         | AY257980     | Thailand        | 1,575       |
| CHAND03      | AY987478     | India           | 1,592       |
| MALI-HM      | AF325487     | Malaysia        | 2,091       |
| BeijingHu1 G | EU700029     | Beijing, China  | 1,575       |
| GuizhouA10(H) G | EU267745 | Guizhou, China | 1,575       |
| Hebei0(H) G  | EU267752     | Hebei, China    | 1,575       |
| HNDB28 G     | EU008927     | Hunan, China    | 1,575       |
| Hubei0703081 G | EF634518 | Hubei, China   | 2,064       |
| WG430 G      | DQ849060     | Hunan, China    | 1,575       |
| WG432 G      | DQ849059     | Hunan, China    | 1,575       |
| Yunnan_MD06 G | EU253477 | Yunnan, China  | 1,575       |
| Zhejiang Wz1(H) G | EF556198 | Zhejiang, China | 2,067       |
| FY1 G        | DQ849044     | Anhui, China    | 1,575       |
| Yue1 G       | DQ849070     | Guangxi, China  | 1,575       |
| Jiangsu Wx0(H) G | EU267772 | Jiangsu, China | 1,575       |
| NC G         | DQ849064     | Jiangxi, China  | 1,575       |
| CQ92 G       | DQ849072     | Chongqing, China| 1,575       |
| Yunnan_Q07 G | EU275240     | Yunnan, China   | 1,575       |
| YunnanTc06 G | EU275242     | Yunnan, China   | 1,575       |
Phylogenetic analysis of the CTNCEC25 strain with other RABV street and vaccine strains

To further determine the phylogenetic relationship of the CTNCEC25 strain with others RABV strains, especially those recently isolated from different regions in China, two phylogenetic analyses were performed using either the complete genome sequences (Figure 2) or the mature G protein amino acid sequences (Figure 3) of the CTNCEC25 strain and others RABV strains, mainly those recently isolated street strains circulating in China. As expected, at the genomic level, the CTNCEC25 strain was most closely related with the parental CTN-1 strain (Figure 2 and 3), which was consistent with genome comparison analysis (Table 3). Furthermore, compared to other vaccine strains used in China, such as PM and PV, the CTNCEC25 strain was more closely related with those RABV street strains. This phenomenon was even more pronounced when the phylogenetic tree was built based on the mature G protein amino acid sequences, in which the CTNCEC25 strain was clustered together with almost all of the selected recently isolated China RABV street strains while other commonly used vaccine strains were clustered into another group together with only a few China RABV street strains (Figure 3). Therefore, the above results suggested that the CTNCEC25 strain was phylogenetically more closely related with those native China RABV street isolates than other vaccine strains commonly used in China.

Virus replication in cell culture

To compare the infectivities of the CTN-1 and CTNCEC25 strains in both neuronal NA cells and the nonneuronal Vero or CECs, viral replication was examined by analysis of progeny virus production in NA, Vero or CECs infected with CTN-1 or CTNCEC25 at a multiplicity of infection (MOI) of 3 fluorescent focus units (FFUs)/cell. As illustrated in Figure 4A and B, the viral titers of the CTNCEC25 strain in both NA and Vero cells were comparable to that of the parental CTN-1 strain and similar growth kinetics were observed for these two viruses with peak titers at 72 hours post infection (h p.i.) reaching about 10^8.0 FFUs/ml. As expected, CTNCEC25 replicated at a similar robustness and reached high titers in CECs, although the titers were slightly lower than that in NA or Vero cells (Figure 4C). On the other hand, the CTN-1 strain was previously maintained in Vero cells, it replicated poorly in CECs and the titers at 72 and 96 h p.i. were approximately 100-fold lower than that of the CEC-adapted CTNCEC25 strain (Figure 4C). Therefore, the results indicated that the adaptation of CTNCEC25 to CECs did not affect virus replication in cultured cells.

Discussion

In the present study, the complete genome of the RABV strain CTNCEC25, the first CTN-1 strain adapted to CECs, was sequenced and analyzed. The results demonstrated that the CTNCEC25 strain was closely related to China RABV street strains recently isolated from different regions. Furthermore, although the CTNCEC25
strain achieved stable and high titers in cultured cells and CECs (Figure 4), it caused no lethality in adult mice by intracerebral inoculation [32], thus providing a rationale for its potential use for human vaccine production in China.

Comparison of the nucleotide sequences of CTNCEC25 with CTN-1 identified that all nucleotide changes occurred in the structural protein genes, with the G gene being the most variable. Similar results were observed in another attenuated RABV strain, RC-HL, which was derived from the RABV Nishigahara strain after 330 passages in chicken embryos and cell cultures [24]. It has been shown that the G gene was the most variable when comparing the complete genome sequences of the RC-HL strain and the Nishigahara strain [39]. Given that RABV is highly neurotropic in nature and the fact the G protein is the major structural protein involved in the neurotropism of RABV by recognizing receptors on neurons, it is therefore not unexpected that the G protein underwent greater selection pressure during adaptation to cultured nonneuronal cells.

Previous studies have identified several amino acids in G protein that were important for the antigenicity and pathogenicity of RABV [22,23]. In the present study, two of these critical amino acids, aa 147 and 333, were found to be mutated in CTNCEC25 G protein during adaptation to CECs. Therefore, it was assumed that the pathogenicity of CTNCEC25 may be severely attenuated in adult mice, which was consistent with our previous in vivo study showing that CTNCEC25 was apathogenic to adult mice by intracerebral inoculation [32].

Sequence analysis identified that the Lyssavirus genome contains the signals essential for the transcription initiation, termination and processing for all the five structural protein genes, and the RABV is no exception [4]. A consensus sequence, 3'-A/U-C-U-U-U-U-U-U-U-5', is conserved in all of the five RABV structural protein genes [3]. Several studies using Vesicular stomatitis virus (VSV), the prototype of the Vesiculovirus genus, showed that the U7 tract is strictly conserved and essential for VSV mRNA termination and polyadenylation, and either shortening or interrupting it with a heterologous nucleotide eliminates mRNA termination and polyadenylation [40,41]. As is the case for CTNCEC25, however, the U7 tract is only conserved in four of the five structural protein genes, N, M, G and L, but not the P gene, in which the U7 tract was shortened to U6. Therefore, it is assumed that the expression of M gene, which is located downstream of the P gene, would be affected in CTNCEC25 due to the read-through of the upper P gene. Previous studies have revealed that the M gene encodes a multifunctional protein that plays essential roles not only in mediating viral assembly and budding but also in regulating the balance between the transcription and replication of RABV. So the disruption of M gene expression should certainly impair the CTNCEC25 replication in cultured cells. Although we did not perform transcriptional analysis

Table 5 Homologies of the ectodomain amino acid sequences of the CTNCEC25 G protein with those of other virus strains

| Strain   | Identity (%) | Strain   | Identity (%) |
|----------|--------------|----------|--------------|
| CTN-1    | 99.1         | SH2RV 18 | 90.9         |
| SRV9     | 93.8         | BeijingHu1 | 95.9       |
| SAG2     | 94.5         | GuizhouA11(H) | 94.1      |
| ERA      | 94.8         | Hebei0(H) | 94.8        |
| SAD B19  | 94.5         | HNDB28  | 95.9        |
| HEP-Flury| 95.2         | Hubei0703081 | 95.7     |
| FluryLPE | 94.8         | WG430   | 95.7        |
| PM1503   | 93.8         | WG432   | 95.7        |
| PV       | 94.8         | Yunan_MD06 | 95.2      |
| 3aG      | 93.6         | Zhejiang Wz1(H) | 95.7    |
| HN10     | 97.9         | FY1     | 95.4        |
| BD06     | 95.2         | Yue1    | 95.4        |
| DV       | 90.0         | Jiangsu Wx0(H) | 94.5     |
| MRV      | 93.2         | NC      | 95.9        |
| FJ008    | 95.4         | CQ92    | 97.0        |
| D01      | 95.4         | Yunan_Q07 | 95.2      |
| JX08-45  | 96.6         | YunnanTc06 | 95.7     |
| RV-97    | 92.5         | MAL1-HM | 96.1        |
| Nishigahara | 94.1     | CHAND03 | 94.5        |
| 8743THA  | 95.2         | NNV-RAB-H | 96.1      |
of the CTNCEC25 M gene, this possibility could be ruled out as the growth kinetics of CTNCEC25 in cultured cells were indistinguishable from that of CTN-1 (Figure 4).

After careful inspection of the database, we found that while the typical U7 tract was the preponderant sequence at the P-M junction, several types of disruption of the typical U7 tract were observed, although with a low frequency, in the P-M junctions, including shortening or lengthening of U7 tract to U6 or U8 and interruption of the U7 tract by a different nucleotide (Figure 1). Therefore, it is possible that the RABV street strains have accumulated mutations during evolution and maintained these mutations to increase their population diversity, better adapt to their hosts or disseminate infection to a new host species. On the other hand, it also cannot rule out the possibility that different mechanisms may exist upon the molecular biology between RABV and VSV, as RABV and VSV share distinct natural histories and pathogenicity despite the close relationship within each other [4]. Further studies are needed to unravel the mechanisms underlining the regulation of gene expression of CTNCEC25.

Phylogenetic analysis using the genome sequence or the mature G protein amino acid sequence identified that CTNCEC25 shared high homology with wild strains isolated from different regions in China. It has been previously reported that the identity of the ectodomain amino acid sequence of RABV G protein directly correlates with the efficacy of vaccination and VNAs displayed cross-protection only when the amino acid sequence of the G protein ectodomain was at least 74% identical [31]. The recent antigenic analysis using serological assay data has also demonstrated that a 4.8% change in the G protein ectodomain amino acid sequence would cause a change of one antigenic unit between viruses (equivalent

---

**Figure 2** Phylogenetic analysis of the complete genome sequence of CTNCEC25 compared with other RABV strains. The tree was constructed using the Neighbor-Joining algorithm in MEGA 4.0 software. The numbers below the branches are bootstrap values for 1000 replicates. CTNCEC25 was marked with a black star.
Figure 3 Phylogenetic analysis of the mature G protein amino acid sequences of CTNCEC25 compared with other RABV strains. The tree was constructed using the Neighbor-Joining algorithm in MEGA 4.0 software. The numbers below the branches are bootstrap values for 1000 replicates. CTNCEC25 was marked with a black star.
to a two-fold change in antibody titer) and there is a generally good correlation between genetic distance in the G protein and antigenic distance [42]. Therefore, it is reasonable that the best vaccine strain should be the one most closely related to the street strains circulating within the target area. Sequence analysis showed that compared to aG, PM and PV vaccine strains, which were widely used in China for human vaccine production, the CTNCEC25 strain was more closely related to RABV strains circulated in China while the other three vaccine strains were predominantly clustered with RABV strains derived from other countries. In addition, the ectodomain amino acid homology of the G proteins of CTNCEC25 with other RABV strains ranged from 90.0% to 99.1% (Table 5), which significantly ranked above the threshold 74% for the presence of cross-protection. Taken together, the above results indicated that CTNCEC25 was an ideal candidate for human vaccine production in China.

The human rabies vaccines can be produced either from animal tissues or cultured cells, such as CECs, BHK or Vero cells [43]. The development of modern industrial cell cultivation and fermentation techniques have greatly promoted the capacity of producing vaccines with high quantity and quality. Given the consideration of purity and concentration of vaccines, vaccines using cultured cells have quickly outdated the use of tissue-derived rabies vaccines. However, although cell culture vaccines are highly efficacious and immunogenic, these cell lines may have differences in genotypes or phenotypes from the original cell line and thus may contain oncogenic properties [44,45]. Therefore, great caution should be taken in using such cell lines for vaccine manufacturing. Specific guidelines for producing human vaccines using the continuous cell lines were enacted in China and no more than 100 pg of host cellular DNA per dose was allowed for authorized vaccine production using Vero cell line according to the standard of the Pharmacopoeia of the People’s Republic of China (2010), Volume III. On the other hand, CECs, which have limited life span than continuous cell lines, maintain the normal cellular karyotype and thus guarantee no contamination of foreign and oncogenic particles and are expected to be a promising substitute substrate for production of safe human vaccine [43]. The FluryLEP strain has already been adapted to CECs to produce purified chicken embryo cells vaccines, and has been recommended by WHO and widely used in many countries due to its high safety and efficacy, low cost and relative simple manufacturing techniques [46-49]. Current vaccine production in China was almost exclusively based on Vero cells, making vaccine strains adapted to CECs urgently needed.

Conclusion
In this study, an CECs-adapted RABV strain CTNCEC25 was sequenced and characterized. Phylogenetic analysis
identified that CTNCEC25 was more closely related to RABV street strains circulating in China than other RABV vaccine strains currently used in China. Sequence comparison showed that the G protein ectodomain amino acid sequence identity between CTNCEC25 and other RABV strains was at least 90% identical. Furthermore, CTNCEC25 produced high virus titers in primary culture cells while it lacked the pathogenicity for adult mice. Collectively, these results demonstrated that the CTNCEC25 strain is an ideal vaccine strain candidate for producing human vaccine with high quality and safety in China.

Materials and methods

Viruses and cells
The CTN-1 strain (after 5 passages in Vero cell lines) was obtained from National Institute for the Control of Pharmaceutical and Biological Products (NICPBP). The CTNCEC25 strain was prepared by adapting the CTN-1 strain to CECs through serial passage in CECs [32], and passage 36 of the CTNCEC25 strain in CECs was used in this study unless otherwise specified. BSR cells (cloned from BHK-21), CECs and Vero cells were maintained in M199 (Invitrogen) supplemented with 10% fetal bovine serum (FBS). Mouse neuroblastoma NA cells were grown in Eagle’s minimal essential medium supplemented with 10% FBS. All cells were incubated at 37°C in 5% CO₂.

Primer design
According to the conserved regions of the genome sequence of the CTN-1 strain published in GenBank (GenBank accession no. FJ959397), 13 pairs of primers were designed to amplify the regions of CTNCEC25 strain using DNASTAR 7.0 software (DNASTAR Inc., Madison, WI, USA) and synthesized and purified using PAGE purification by Invitrogen (Table 1).

RNA extraction, reverse transcription-PCR and direct sequencing
Total RNA was extracted from supernatants of CTNCEC25 infected CECs using the QIAampViral RNA Mini Kit (Qiagen) according to manufacturer’s instructions. The first strand of cDNA was synthesized using the First Strand cDNA Synthesis Kit (TOYOBO) and the cDNA was amplified using the Platinum Taq DNA HIF I Polymerase (Invitrogen), according to the manufacturer's protocols. Then, the full-length cDNA was subjected to nucleotide sequencing straightly by BGI-Beijing (Beijing, China) and Invitrogen Life Technologies Corporation (Shanghai, China) using the Chain Termination Method. The nucleotide sequence of the full-length genome of CTNCEC25 was submitted to GenBank under accession no. KJ466147.

Sequence alignment and phylogenetic analysis
The nucleotide sequences obtained were edited manually using the DNASTAR 7.0. Multiple sequence alignments were constructed using Clustal X [50] with default settings. Phylogenetic trees were constructed on the basis of multiple alignments using the neighbor-joining algorithm in the software package MEGA 4. The reliability of the phylogeny groupings was evaluated using bootstrapping with 1000 replicates. The RABV strains with complete genome or the G gene sequence available in the GenBank used in this study were listed in Table 2.

Virus titration
The virus titer was determined using a modified rapid fluorescence focus inhibition test as previously described [51] and expressed in FFUs/ml. Briefly, a monolayer of BSR cells in 96-well plates was incubated with serial three-fold virus dilutions. At 24 h p.i., the cells were fixed with 80% ice-cold acetone and stained with a FITC-labeled monoclonal antibody against nucleoprotein (Millipore) for 1 h at 37°C. The plates were examined by fluorescence microscopy, and the number of fluorescent foci presented in the wells was recorded. Endpoints were defined as the highest dilutions with fluorescent foci less than 30, and virus titers were calculated by the following formula: virus titer (FFU/ml) = (the mean foci number in the endpoint wells × 5 + the mean foci number in the wells with lower dilutions next to the endpoint well) ÷ 2 × the dilution factor of the lower dilutions × 20.

Virus growth analysis in cultured cells
NA, Vero and CEC cells (1 × 10⁶) were infected with the indicated viruses at an MOI of 3 FFUs/ml for single-step growth analysis as previously described [39]. Briefly, after 1 h of incubation at 37°C, the inoculum was removed and cells were washed three times with Hanks’ balanced salt solution, then 3 ml of the corresponding fresh medium was added to the cells. Cells were incubated at 37°C in 5% CO₂ and supernatants were harvested at the indicated time points. Titration of viral stocks was performed by an direct immunofluorescence assay as described above.

Abbreviations
RABV: Rabies virus; CNS: Central nervous system; RNP: Ribonucleoprotein; CECs: Chick embryo cells; nt: Nucleotides; CDC: Coding sequence; FFU: Fluorescent focus unit; MOI: Multiplicity of infection; p.i.: Post infection; i.c.: Intracerebral; VNA: Virus-neutralizing antibody.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
SMZ carried out the design of the study, experimental implementation and the data analysis. CHW participated in the design of the study and data analysis. PZ and HL performed gene sequencing analysis and the animal experiment. SL performed cell culturing, viral passage and viral titer determination. CPG is the corresponding author and provided overall supervision of the study. All authors have read and approved the final manuscript.
Acknowledgements

We are grateful to Pro. Yongxin Yu (National Institutes for Food and Drug Control) for generous technical assistance and advice. We also acknowledge support from Pres. Jincai Wang (Shenzhen Weiguang Biological Products Co., Ltd.). This work was financially supported by Guangdong Engineering Research and Development Center.

Received: 27 May 2014 Accepted: 22 September 2014
Published: 6 October 2014

References

1. Dietzschold B, Schnell M, Koprowski H: Pathogenesis of rabies. Curr Top Microbiol Immunol 2005, 292:45–56.
2. Zhang YZ, Xiong CL, Xiao DL, Jiang RJ, Wang ZX, Zhang LZ, Fu ZF: Human rabies in China. Emerg Infect Dis 2005, 11:983–1984.
3. Tordo N, Poch O, Ermine A, Keith G, Rougeon F: Walking along the rabies genome: is the large G–L intergenic region a remnant gene? Proc Natl Acad Sci U S A 1986, 83:3914–3918.
4. Albertini AA, Ruijgrok RW, Blondel D: Rabies virus transcription and replication. Adv Virus Res 2011, 79:1–22.
5. Metabotin T, Weiland F, Conzelmann KK: Matrix protein of rabies virus is responsible for the assembly and budding of bullet-shaped particles and interacts with the transmembrane spike glycoprotein G. J Virol 1999, 73:242–250.
6. Metabotin T, Konig M, Conzelmann KK: Budding of rabies virus particles in the absence of the spike glycoprotein. Cell 1996, 84:949–951.
7. Cox JH, Dietzschold B, Schneider LG: Rabies virus glycoprotein. II. Biological and serological characterization. Infect Immun 1977, 16:754–759.
8. Wiktor T, Gyorgy E, Schlumberger D, Sokol F, Koprowski H: Antigenic properties of rabies virus particles. J Immunol 1973, 110:269–276.
9. Zhu JH, Wang J, Cai B, Zhao W, Zhu Y, Chao R, Chen L, Xue Y, Ying BL, Li CP, Hu QL, Sha J, Esposito J: Immunogenicity and relative attenuation of different vaccinia-rabies virus recombinants. Arch Virol 1996, 141:1055–1065.
10. Faber M, Pulmanausahakul R, Hodavadekar SS, Spitsin S, Metztinger JP, Schnell MJ, Dietzschold B: Overexpression of the rabies virus glycoprotein results in enhancement of apoptosis and antiviral immune response. J Virol 2002, 76:3374–3381.
11. Dietzschold B, Wunner WH, Wiktor T, Lopes AD, Lofan M, Smith CL, Koprowski H: Characterization of an antigenic determinant of the glycoprotein that correlates with pathogenicity of rabies virus. Proc Natl Acad Sci U S A 1983, 80:70–74.
12. Morimoto K, Hooper DC, Spitsin S, Koprowski H, Dietzschold B: Pathogenicity of different rabies virus variants inversely correlates with apoptosis and rabies virus glycoprotein expression in infected primary neuron cultures. J Virol 1999, 73:510–514.
13. Morimoto K, Foley HD, Metztinger JP, Schnell MJ, Dietzschold B: Reinvestigation of the role of the rabies virus glycoprotein in viral pathogenesis using a reverse genetics approach. J Neurovirol 2000, 6:373–381.
14. Self L, Coulon P, Rollin PE, Flamand A: Rabies virulence: effect on pathogenicity and sequence characterization of rabies virus mutations affecting antigenic site III of the glycoprotein. J Virol 1985, 53:926–934.
15. Lentz TL, Wilson PT, Hawrot E, Speicher DW: Amino acid sequence similarity between rabies virus glycoprotein and snake venom curareimetics neurotoxins. Science 1984, 226:847–848.
16. Thoukouzu MI, Lafage M, Schachner M, Hartmann U, Cremers H, Lofan M: The neural cell adhesion molecule is a receptor for rabies virus. J Virol 1998, 72:1781–7190.
17. Langevin C, Iaro H, Bressollet S, Fainzilber M, Tuffereau C: Rabies virus glycoprotein (RVG) is a trimeric ligand for the N-terminal cysteine-rich domain of the mammalian p75 neurotrophin receptor. J Biol Chem 2002, 277:37655–37662.
18. Tuffereau C, Benezet J, Blondel D, Klefber F, Flamand A: Low-affinity nerve-growth factor receptor (PTSN75TR) can serve as a receptor for rabies virus. EMBO J 1998, 17:250–2529.
19. Bemnmsour A, Leblois H, Coulon P, Tuffereau C, Gaudin Y, Flamand A, Lafay F: Antigenicity of rabies virus glycoprotein. J Virol 1991, 65:4198–4203.
20. Dietzschold B, Gore M, Marchadier D, Niu HS, Bunschoten HM, Otvos L Jr, Wunner WH, Erts HC, Osterhaus AD, Koprowski H: Structural and immunological characterization of a linear virus-neutralizing epitope of the rabies virus glycoprotein and its possible use in a synthetic vaccine. J Virol 1990, 64:3804–3809.
21. van der Heijden RW, Langedijk JP, Groen J, Uytteldhaag FG, Meloen RH, Osterhaus AD: Structural and functional studies on a unique linear neutralizing antigenic site (G5) of the rabies virus glycoprotein. J Gen Virol 1993, 74(Pt 8):1539–1545.
22. Prehaut C, Coulon P, Lafay F, Thiern C, Flamand A: Antigenic site II of the rabies virus glycoprotein: structure and role in viral virulence. J Virol 1989, 62:1–7.
23. Faber M, Faber ML, Papani A, Bette M, Wiehe E, Dietzschold B, Schnell MJ: A single amino acid change in rabies virus glycoprotein increases virus spread and enhances virus pathogenicity. J Virol 2005, 79:14141–14148.
24. Tuffereau C, Ito N, Yamada K, Minamoto N, Sugiyama M, Region at amino acids 164 to 303 of the rabies virus glycoprotein plays an important role in pathogenicity for adult mice. J Neurovirol 2004, 10:131–135.
25. Takayama-Ito M, Ito N, Yamada K, Minamoto N, Sugiyama M, Region at amino acids 164 to 303 of the rabies virus glycoprotein plays an important role in pathogenicity for adult mice. J Neurovirol 2004, 10:131–135.
26. Rupprecht CE, Barrett J, Briggs D, Cliquet F, Focks AR, Lumlertdacha B, Meslin FX, Muler T, Nel LH, Schneider C, Tordo N, Wanderl A: Can rabies be eradicated? Dev Biol (Basel) 2008, 131:95–121.
27. Rupprecht CE, Hanlon CA, Slate D: Control and prevention of rabies in animals: paradigm shifts. Dev Biol (Basel) 2006, 125:103–111.
28. Du J, Zhang Q, Li Q, Li H, Tao X, Morimoto K, Nadim-Davis SA: Characterization of human rabies virus vaccine strain in China. Virus Res 2008, 135:260–266.
29. Jiao W, Yin X, Li Z, Lan X, Li X, Tian X, Li B, Yang B, Zhang Y, Liu J: Molecular characterization of China rabies virus vaccine strain. Virol J 2011, 8:521.
30. Cai L, Tao X, Liu Y, Zhang H, Gao L, Hu S, Liu F, Li H, Shen X, Liu J, Wang S, Tang Q: Molecular characteristics and phylogenetic analysis of 5 gene of human derived rabies virus. Bior Inform Sci V 2011, 24:431–437.
31. Badrane H, Bahoul C, Petin P, Tordo N: Evidence of two Lyssavirus phylogroups with distinct pathogenicity and immunogenicity. J Virol 2001, 75:3268–3276.
32. Guo C, Wang C, Luo S, Zhu S, Li H, Liu Y, Zhou L, Zhang P, Zhang X, Ding Y, Huang W, Wu K, Zhang Y, Rong W, Tian H: The adaptation of a CTN-1 rabies virus strain to high-titered growth in chick embryo cells for vaccine development. Virol J 2014, 11:85–92.
33. Wertz GW, Moudy R, Ball LA: Adding genes to the RNA genome of vesicular stomatitis virus: positional effects on stability of expression. J Virol 2002, 76:7642–7650.
34. Prehaut C, Hekkerbrand E, Coudrier D, Volkov V, Volkovka VA, Feldmann H, Le Guenno B, Bouloy M: Recombinant Ebola virus nucleoprotein and glycoprotein (Gabon 94 strain) provide new tools for the detection of human infections. J Virol 1998, 72:3551–3572.
35. Diao L: Avirulent mutants of the rabies virus: change in site III of the glycoprotein. Ann Rev Vet 1986, 173:6–3.
36. Tuffereau C, Leblois H, Benezet J, Coulon P, Lafay F, Flamand A: Arginine or lysine in position 333 of ERA and CVS glycoprotein is necessary for rabies virulence in adult mice. Virology 1989, 172:206–212.
37. Metabotin T, Weiskirchen B, Koeppen C, Bouloy M, Urgenzini C, Metztinger JP, Schnell MJ, Dietzschold B: Genetic engineering of live rabies vaccines. Adv Virus Res 1998, 53:341–364.
38. Morimoto K, McElhinney LM, Marston DA, Wood JL, Russell CA, Lewis N, Zhu Z, Kuzmin IV, Fouchet RA, Osterhaus AD, Fooks AR, Smith DJ: Quantifying antigenic relationships among the lyssaviruses. J Virol 2010, 84:19141–19148.
43. Wu X, Smith TG, Rupprecht CE: From brain passage to cell adaptation: the road of human rabies vaccine development. Expert Rev Vaccines 2011, 10:1597–1608.
44. Manohar M, Ornston B, Peden K, Lewis AMJ: Assessing the tumorigenic phenotype of VERO cells in adult and newborn nude mice. Biologics 2008, 36:65–72.
45. Levenbook IS, Petricciani JC, Elsberg BL: Tumorigenicity of Vero cells. J Biol Stand 1984, 12:391–398.
46. Barth R, Gruschka H, Björk U, Hilfenhaus J, Hinz J, Milck L, Moser H, Jaeger O, Ronneberger H, Weinmann E: A new inactivated tissue culture rabies vaccine for use in man. Evaluation of PCEC-vaccine by laboratory tests. J Biol Stand 1984, 12:29–46.
47. Kondo A: Pre-immunization and post-exposure treatment with inactivated rabies vaccine of chick embryo cell culture origin (CEC). Dev Biol Stand 1978, 40:147–153.
48. Nicholson KG, Farrow PR, Björk U, Barth R: Pre-exposure studies with purified chick embryo cell culture rabies vaccine and human diploid cell vaccine: serological and clinical responses in man. Vaccine 1987, 5:208–214.
49. Kamoltham T, Thinyounyong W, Phongchamnaphai P, Phraisuwan P, Khawplod P, Banhoff A, Makerczyk C: Pre-Exposure Rabies Vaccination Using Purified Chick Embryo Cell Rabies Vaccine Intradermally is Immunogenic and Safe. J Pediatr 2007, 151:173–177.
50. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, Valentin F, Wallace IM, Wilm A, Lopez R, Thompson JD, Gibson TJ, Higgins DG: Clustal W and Clustal X version 2.0. Bioinformatics 2007, 23:2947–2948.
51. Smith JS, Yager PA, Baer GM: A rapid reproducible test for determining rabies neutralizing antibody. Bull World Health Organ 1973, 48:535–541.

doi:10.1186/1743-422X-11-176
Cite this article as: Zhu et al.: Sequencing and molecular characterization of CTNCEC25, a China fixed rabies virus vaccine strain CTN-1 adapted to primary chicken embryo cells. Virology Journal 2014 11:176.